Qube Research & Technologies LTD Blueprint Medicines Corp Transaction History
Qube Research & Technologies LTD
- $93.8 Billion
- Q2 2025
A detailed history of Qube Research & Technologies LTD transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Qube Research & Technologies LTD holds 66,275 shares of BPMC stock, worth $8.58 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
66,275
Previous 337,151
80.34%
Holding current value
$8.58 Million
Previous $29.8 Million
71.53%
% of portfolio
0.01%
Previous 0.04%
Shares
11 transactions
Others Institutions Holding BPMC
# of Institutions
390Shares Held
66.9MCall Options Held
973KPut Options Held
1.54M-
Black Rock Inc. New York, NY6.65MShares$861 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.42MShares$831 Million0.01% of portfolio
-
Pentwater Capital Management LP Naples, FL3.9MShares$505 Million3.34% of portfolio
-
Jpmorgan Chase & CO New York, NY2.51MShares$324 Million0.02% of portfolio
-
State Street Corp Boston, MA2.23MShares$289 Million0.01% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $7.73B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...